Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polymorphic marker that can be used to assess the efficacy of interferon therapy

A technology of interferon and interferon α, which is applied in special data processing applications, microbial measurement/inspection, instruments, etc., and can solve the problems of waste of patient health care funds, large changes in IFNα/β efficacy, high treatment period and treatment price, etc.

Inactive Publication Date: 2008-05-21
KK TOSHIBA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, IFNα / β potency has been reported to vary widely depending on host and viral factors
[0004] Considering the considerable side effects associated with IFN therapy, the prolonged treatment period and the high price of the treatment, treating a patient with IFN without expecting a successful outcome is not only a pain for the patient but also a huge waste of healthcare funds paid by the patient or the state

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymorphic marker that can be used to assess the efficacy of interferon therapy
  • Polymorphic marker that can be used to assess the efficacy of interferon therapy
  • Polymorphic marker that can be used to assess the efficacy of interferon therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0116] 1. Confirmation of IFNRA1 gene and IFN curative effect

[0117] 1-1. Part I

[0118] Determine the virus type, IFNAR1 gene SNP and microsatellite marker type in each patient, and study the relationship between these indicators and curative effect.

[0119] (1) Summary

[0120] DNA and RNA were extracted from blood samples of 138 HCV-infected patients and used as analysis samples. The virus was typed using the RNA component, and the SNP of the IFNAR1 gene was analyzed using the DNA and the microsatellite markers were typed. Subsequently, the relationship between the efficacy of IFNα / β and virus type, SNP of IFNAR1 gene or microsatellite marker was investigated.

[0121] (2) Patient

[0122] In this study, samples from 138 HCV-infected patients who had been confirmed to have chronic hepatitis C based on blood biochemical examination, histological examination and liver imaging analysis were used. All patients gave informed consent to participate in this study. During...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a polymorphism sign found in an area of interferon receptor gene, which can be used for evaluating the curative effect of the interferon. Therefore, the invention also relates to the method for evaluating the personal curative effect of interferon and the device for finishing the method.

Description

[0001] This application is a divisional application of the Chinese Invention Patent Application No.02800431.0 with the filing date of September 20, 2002, and the title of the invention is "Polymorphic markers that can be used to evaluate the efficacy of interferon". technical field [0002] The present invention relates to polymorphic markers found in a region of the interferon receptor gene that can be used to assess the efficacy of interferon. Accordingly, the present invention also relates to methods of assessing the efficacy of interferons in individuals, and devices for carrying out such methods. Background technique [0003] In Japan, about 2,000,000 individuals are infected with hepatitis C virus (hereinafter abbreviated as HCV). About 70% of infected individuals develop chronic hepatitis, and some of them are thought to develop liver cancer after 10 to 20 years. Such chronic hepatitis can be effectively treated with interferon (hereinafter abbreviated as IFN) alpha ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G06F19/00
Inventor 松山德子杉本正信桥本美智惠三代俊治
Owner KK TOSHIBA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com